These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27218790)

  • 41. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
    Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
    Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
    Tauber G; Pavlovsky L; Fenig E; Hodak E
    J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma.
    Amin SH; Motamedi KK; Ochsner MC; Song TE; Hybarger CP
    Discov Med; 2013 Nov; 16(89):229-32. PubMed ID: 24229739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
    Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.
    Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P
    Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
    Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
    Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
    Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
    Zhu GA; Sundram U; Chang AL
    JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases.
    Bancalari B; Llombart B; Serra-Guillén C; Bernia E; Requena C; Nagore E; Traves V; Calomarde L; Diago A; Guillén C; Sanmartín O
    Am J Dermatopathol; 2019 Oct; 41(10):711-717. PubMed ID: 31436575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
    Patel S; Armbruster H; Pardo G; Archambeau B; Kim NH; Jeter J; Wu R; Kendra K; Contreras CM; Spaccarelli N; Dulmage B; Pootrakul L; Carr DR; Verschraegen C
    PLoS One; 2024; 19(4):e0297531. PubMed ID: 38687774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
    Fife D; Laitinen MA; Myers DJ; Landsteiner PB
    Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
    Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
    Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
    Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
    Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
    Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
    Alcalay J; Tauber G; Fenig E; Hodak E
    J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
    Yin VT; Esmaeli B
    Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.